Cellectar Biosciences, Inc.
CLRB · NASDAQ
Bulios Fair Price
$1.3
45.4% downside
Current Price
$2.38
According to Bulios Fair Price, CLRB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Cellectar Biosciences, Inc. is a biotechnology company focused on developing innovative drugs for the diagnosis and treatment of cancer. Their main product is a technology based on molecular probes that enable targeted detection and treatment of cancer cells. This technology is designed to increase the sensitivity and accuracy of cancer diagnostics and allow for selective therapeutic effects on tumor cells with minimal side effects. Cellectar Biosciences, Inc. is developing various products utilizing this technology, including diagnostic probes and therapeutic drugs, which may bring new options in cancer treatment and improve patient prognosis.
Sector
Healthcare
Industry
Biotechnology
CEO
James V. Caruso
Employees
11
Headquarters
Florham Park
Upcoming events
Earnings
Upcoming earnings report